Glucose deprivation increases tau phosphorylation via P38 mitogen‐activated protein kinase

Alterations of glucose metabolism have been observed in Alzheimer's disease (AD) brain. Previous studies showed that glucose deprivation increases amyloidogenesis via a BACE‐1‐dependent mechanism. However, no data are available on the effect that this condition may have on tau phosphorylation. In this study, we exposed neuronal cells to a glucose‐free medium and investigated the effect on tau phosphorylation. Compared with controls, cells incubated in the absence of glucose had a significant increase in tau phosphorylation at epitopes Ser202/Thr205 and Ser404, which was associated with a selective activation of the P38 mitogen‐activated protein kinase. Pharmacological inhibition of this kinase prevented the increase in tau phosphorylation, while fluorescence studies revealed its co‐localization with phosphorylated tau. The activation of P38 was secondary to the action of the apoptosis signal‐regulating kinase 1, as its down‐regulation prevented it. Finally, glucose deprivation induced cell apoptosis, which was associated with a significant increase in both caspase 3 and caspase 12 active forms. Taken together, our studies reveal a new mechanism whereby glucose deprivation can modulate AD pathogenesis by influencing tau phosphorylation and suggest that this pathway may be a new therapeutic target for AD.

[1]  D. Praticò,et al.  Gamma Secretase-Activating Protein Is a Substrate for Caspase-3: Implications for Alzheimer’s Disease , 2015, Biological Psychiatry.

[2]  H. Ichijo,et al.  Inhibition of ASK1-p38 pathway prevents neural cell death following optic nerve injury , 2012, Cell Death and Differentiation.

[3]  K. Nakanishi,et al.  An Endoplasmic Reticulum Stress-specific Caspase Cascade in Apoptosis , 2002, The Journal of Biological Chemistry.

[4]  G. Mills,et al.  Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Ammit,et al.  Targeting p38 MAPK pathway for the treatment of Alzheimer's disease , 2010, Neuropharmacology.

[6]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[7]  Rachel L. Mistur,et al.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M Schulzer,et al.  Cerebral glucose metabolism in Parkinson's disease with and without dementia. , 1992, Archives of neurology.

[9]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[10]  D. Bennett,et al.  Phosphorylation of the Translation Initiation Factor eIF2α Increases BACE1 Levels and Promotes Amyloidogenesis , 2008, Neuron.

[11]  Won Taek Lee,et al.  Apoptosis Signal Regulating Kinase 1 (ASK1): Potential as a Therapeutic Target for Alzheimer’s Disease , 2014, International journal of molecular sciences.

[12]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[13]  S. Fujita,et al.  Inhibition of Protein Phosphatase 2A Overrides Tau Protein Kinase I/Glycogen Synthase Kinase 3β and Cyclin-dependent Kinase 5 Inhibition and Results in Tau Hyperphosphorylation in the Hippocampus of Starved Mouse* , 2001, The Journal of Biological Chemistry.

[14]  R. Vassar,et al.  Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  G. Fiskum,et al.  Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders , 2007, Journal of neuroscience research.

[16]  W. Markesbery,et al.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study , 2002, Annals of neurology.

[17]  R. Tanzi,et al.  Depletion of GGA3 Stabilizes BACE and Enhances β-Secretase Activity , 2007, Neuron.

[18]  Junying Yuan,et al.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.

[19]  K. Blennow,et al.  Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[20]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[21]  H. Ichijo,et al.  Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. , 2002, Antioxidants & redox signaling.

[22]  T Takahashi,et al.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis , 2001, EMBO reports.

[23]  R. Tanzi,et al.  Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. , 2007, Neuron.

[24]  D. Praticò,et al.  Modulation of AD neuropathology and memory impairments by the isoprostane F2α is mediated by the thromboxane receptor , 2015, Neurobiology of Aging.

[25]  Suzanne Craft,et al.  Insulin and neurodegenerative disease: shared and specific mechanisms , 2004, The Lancet Neurology.

[26]  D. Bredesen,et al.  Tau phosphorylation in Alzheimer’s disease , 2007, NeuroMolecular Medicine.

[27]  S. Santi,et al.  Early detection of Alzheimer’s disease using neuroimaging , 2007, Experimental Gerontology.

[28]  W. Blackstock,et al.  Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass Spectrometry , 2000, Journal of neurochemistry.

[29]  D. Praticò,et al.  Chapter 2 – Alzheimer’s Disease , 2015 .

[30]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[31]  Bryan Maloney,et al.  Transcriptional Regulation of β-Secretase by p25/cdk5 Leads to Enhanced Amyloidogenic Processing , 2008, Neuron.

[32]  P. Mcgeer,et al.  Cortical glucose metabolism in parkinson's and alzheimer's disease , 1990, Journal of neuroscience research.

[33]  D. Praticò,et al.  Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice , 2014, Neurobiology of Aging.